3 hours Is Bristol Myers Squibb Stock a Buy?The Motley Fool

It’s been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company’s financial results dipped following the loss of patent exclusivity of two important medicines in its arsenal: cancer drugs Revlimid (its former top-selling produc…

· ·